A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Ted B. Piorczynski, Yuxuan Liu, Brian Estrella, Edd Ricker, Manuel Pazos, Yulissa Gonzalez, Seda Serra Tolu, Yun Kyoung Tiger, Aleksandar Obradovic, Chang Liu, Charles Karan, Serge Cremers, Renu Nandakumar, Barry H. Honig, Howook Hwang, , Jennifer Effie Amengual
This paper evaluates YF2, a CREBBP/p300 activator, showing it enhances cytotoxicity and immune responses in B-cell lymphoma by restoring acetylation and altering the immune microenvironment.
bioRxiv · Mar 13, 2025 · PreprintCancer Biology